Conference
ACCURACY a phase II trial of AL101, a selective gamma secretase inhibitor, in subjects with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) harboring Notch activating mutations (Notchmut)
Authors
Ferrarotto R; Wirth LJ; Muzaffar J; Rodriguez CP; Xia B; Perez CA; Bowles DW; Winquist E; Hotte SJ; Metcalf R
Volume
31
Publisher
Elsevier
Publication Date
September 2020
DOI
10.1016/j.annonc.2020.08.1034
Conference proceedings
Annals of Oncology
ISSN
0923-7534